Pharmotech SA focuses its Research and Development (R&D) on the potential application potential molecules as antibiotic agent against Multi Drug Resistant bacteria (MDR-MRSA) as Pseudomonas Aeruginosa (PA).
Switzerland is a country with several positive facets, being one of them its topnotch worldwide recognized Universities and laboratories. For this reason Pharmotech SA is conducting its R&D in collaboration with Swiss Primary Scientific Institutions. Pharmotech’s discoveries will certainly help elevate the quality of life of millions of people world wide.
To translate scientific discoveries from the lab bench to the clinic, Pharmotech SA will use proof-of-concept clinical trials to obtain clinical data (small scale studies used to get an early read on a drug’s safety/toxicology and effectiveness) to help find and advance the most promising drug candidates. These proof-of-concept studies often focus on treating well-defined disease.
Pharmotech performed test and trials, in vitro, ex vivo, animals and humans.
Pharmotech SA since 2014 continues actively its R&D program and is following all the steps needed to go on the market. The subjects of the studies are reserved.